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I am delighted to introduce this year’s recipient of the
William Allan Award—Charles J. Epstein. This prize is
the major award of our society and is granted yearly to
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one (or two) scientists for substantial contributions to
human and medical genetics that have been carried out
over a lifetime of scientific and scholarly inquiry. I had
the privilege of chairing this year’s ASHG award com-
mittee. Charlie Epstein clearly emerged as our winner
among many nominations.
I have known Charlie for almost 40 years. We were
fortunate in Seattle that he decided to join our relatively
new division of medical genetics for a postdoctoral fel-
lowship in 1963. Charlie’s credentials were outstanding.
He had a B.S. in chemistry from Harvard College (summa
cum laude), a Harvard M.D. degree (magna cum laude),
followed by 2 years as house officer in internal medicine
at Peter Bent Brigham Hospital in Boston.
Charlie then spent 2 years in Bethesda at the National
Institutes of Health (NIH) with Chris Anfinsen, who
later won the 1970 Nobel Prize in Biochemistry. There,
Charlie received training on various aspects of protein
chemistry and carried out research work in this area. A
number of fine papers—often published in the Journal
of Biological Chemistry—dealt with the genetic control
of the three-dimensional structure of protein.
In planning his future life, a mere laboratory career
in biochemistry did not attract Charlie. Nineteen sixty-
three marked the beginnings of the golden years of hu-
man biochemical genetics, and clinical genetics had just
started. In Seattle, we had initiated a genetics clinic and
also saw patients with genetic diseases on the wards. We
exposed our fellows to think along genetic lines and tried
to fire them up with the great promises of genetic ap-
proaches to medicine, which did not seem quite as clear
at that time as they are today.
Charlie’s principal scientific problem in Seattle was
posed by a patient: could Werner syndrome—an auto-
somal recessive condition with many features of pre-
mature aging—give us clues about the role of the Werner
gene in the normal aging process? Charlie became the
first author of a thorough synthetic analysis of the ge-
netic and clinical manifestation of Werner syndrome,
which remains a standard reference for this disease (Ep-
stein et al. 1966). The genetic problems were clearly set
out at that time, but it took almost 30 more years to
identify the responsible mutation as a helicase gene, by
Schellenberg’s group in Seattle (Yu et al. 1996). Exten-
sive work continues to be carried out in this field, par-
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ticularly by Martin’s group in Seattle (Martin and Osh-
ima 2000). Charlie at all times pointed out that Werner
syndrome should be considered a caricature of aging
rather than a model for the aging process. Much work
on the pathway from genotype to phenotype remains to
be done, since we have few clues how a mutant helicase
causes the characteristic clinical and laboratory findings.
Charlie went on to other pastures. His plan was to
stay only a year in Seattle to be exposed to a human
and medical genetics atmosphere before returning to
NIH in Bethesda, where he continued productively with
his work on various aspects of biochemical human ge-
netics and took on the first small group of what later
became a large number of both research as well as clin-
ical fellows.
In 1967, Charlie moved to the Department of Pediatrics
at the University of California in San Francisco, where
his career blossomed with his work in the biochemical
genetics of metabolic diseases. Note that he was always
open to new challenges. After training in internal medi-
cine, he now largely dealt with children and metamor-
phosed into a pediatrician. Charlie became the consum-
mate physician-scientist, carrying out extensive work both
in the biochemical-genetic laboratory and with patients.
But that was not all! After realizing that elucidation of
critical developmental processes and of pathogenesis
could not be done with humans, Charlie extensively util-
ized the mouse as a model for his research. The early
choice of this species turned out to be an inspired step,
since it turned out that there were many genetic and func-
tional similarities (as well as synteny) between mice and
humans. At that stage of his career, the preimplantation
mouse embryo became the focus of this work. One major
research result was the determination of the timing of X-
chromosome inactivation, as well as demonstrating that
both X chromosomes were active during oogenesis.
Charlie also established a model system for clinical
genetics in San Francisco. He was a pioneer in estab-
lishing criteria and standards of genetic counseling. He
established satellite clinics to demonstrate that the ben-
efits of genetic services and genetic counseling could be
brought to outlying communities. Based on his bio-
chemical skills, prenatal diagnosis of enzyme disorder
became possible for a variety of conditions. Long before
bioinformatics became a buzzword, he set up computer-
based information systems for medical genetics.
Charlie’s clinical activities motivated him to try to
understand the pathogenesis of a common condition in
clinical genetics: Down syndrome. Unlike the monogenic
inborn errors that were relatively well understood based
on the one-gene–one-enzyme paradigm, the develop-
mental and clinical effects of an increased gene activity
in trisomy 21 and other aneuploidies were not so readily
apparent. Were all findings in trisomy 21 caused by in-
creased dosage of various genes on the extra chromo-
some 21, or were there more nonspecific factors at work?
Based on both a broad and in-depth analysis of pheno-
types in various kinds of aneuploidy, Charlie published a
book 15 years ago on The Consequences of Chromosome
Imbalance (Epstein 1986), even before the full impact of
the molecular revolution on genetics had occurred. Char-
lie’s more recent outlook on the pathogenic mechanisms
in Down syndrome is set out in his chapter of Scriver et
al.’s TheMetabolic andMolecular Bases of InheritedDis-
ease (Epstein 2001). Charlie believes in a reductionistic
model to elucidate the developmental and other pheno-
typic effects of the specific genes triplicated in trisomy 21.
This approach led to convincing data for the role of spe-
cific genes in the pathogenesis of Down syndrome.
He drew on ingenious breeding schemes developed by
others, as well as in his own laboratory, to create an
ideal mouse model for Down syndrome. Knockout mice,
transgenic mice, and segmental trisomic mice were em-
ployed to model the specific chromosomal segments that
were triplicated in human trisomy 21. Many exciting
experiments were done. His laboratory has also become
much involved in studies on physiologic states and dis-
eases regarding the role of the superoxide dismutases.
Charlie was never a slave to a single method but
knew how to work with many collaborators who
brought different skills and techniques to his studies.
The important role of his immunologist wife, Lois—
an expert on interferon—should be particularly ac-
knowledged for his early work on Down syndrome.
As we meet here just a month after the worst terror
attack ever launched against our country, let us recall
that Charles Epstein was among the early targets of
terror in the U.S.A. On June 22, 1993, possibly because
of his visibility as the superb editor of The American
Journal of Human Genetics, he was mailed a bomb by
“Unabomber” Ted Kaczynski that almost killed Charlie
and left him with residual injuries. This event affected
Charlie profoundly but did not impair his scientific and
scholarly vigor. The tragedy made him think deeply
about the world, and he also started to write about
societal and ethical aspects of work in human and med-
ical genetics. I recommend his “1996 ASHG Presiden-
tial Address” (Epstein 1997), as well as a more recent
article on ethical implications of the Human Genome
Project (Epstein 2000). I also know that he is writing
a book about his views on these matters. Dealing with
terror may be affecting all of us in the future. We can
look to Charlie as a guide in our efforts to help us
come to grips with these challenges.
As a mentor, friend, and colleague, I am proud and
delighted to present the 2001 William Allan Award to
Charles Epstein for his pioneering role in scientific and
scholarly inquiry complemented by his major impact
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on many aspects of human and medical genetics. We
all respect, revere, and love him!
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